London, United Kingdom–(Newsfile Corp. – June 26, 2025) – Edison issues report on Lamda Development (ASE: LAMDA).
LAMDA Development is the largest mall owner and operator in Greece and is currently developing The Ellinikon, Europe’s biggest urban regeneration project. LAMDA’s core mall portfolio will expand to six developments, plus two existing yacht marinas with a third marina expected to be operational in 2028-29. The cash flows from the core operations support the development of the ambitious Ellinikon project, which aims to become a value-creating ‘city within a city’ by 2037 as LAMDA builds out the two development phases. Lamda values the existing mall and marina operations plus Phase 1 at c €12.30 per share.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256912
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…